Divided method of intercostal nerve block reduces ropivacaine dose by half in thoracoscopic pulmonary resection while maintaining the postoperative pain score and 4-h mobilization: a retrospective study
- PMID: 37561173
- PMCID: PMC10543147
- DOI: 10.1007/s00540-023-03229-w
Divided method of intercostal nerve block reduces ropivacaine dose by half in thoracoscopic pulmonary resection while maintaining the postoperative pain score and 4-h mobilization: a retrospective study
Erratum in
-
Correction to: Divided method of intercostal nerve block reduces ropivacaine dose by half in thoracoscopic pulmonary resection while maintaining the postoperative pain score and 4-h mobilization: a retrospective study.J Anesth. 2023 Dec;37(6):979. doi: 10.1007/s00540-023-03266-5. J Anesth. 2023. PMID: 37792137 Free PMC article. No abstract available.
Abstract
Purpose: This study investigated whether the divided method of multi-level intercostal nerve block (ML-ICB) could reduce the ropivacaine dose required during thoracoscopic pulmonary resection, while maintaining the resting postoperative pain scores.
Methods: This retrospective, single-cohort study enrolled 241 patients who underwent thoracoscopic pulmonary resection for malignant tumors between October 2020 and March 2022 at a cancer hospital in Japan. ML-ICB was performed by surgeons under direct vision. The differences in intraoperative anesthetic use and postoperative pain-related variables at the beginning and end of surgery between group A (single-shot ML-ICB; 0.75% ropivacaine, 20 mL at the end of the surgery) and group B (divided ML-ICB, performed at the beginning and end of surgery; 0.25% ropivacaine, 30 mL total) were assessed. The numerical rating scale (NRS) was used to evaluate pain 1 h and 24 h postoperatively.
Results: Intraoperative remifentanil use was significantly lower in group B (14.4 ± 6.4 μg/kg/h) than in group A (16.7 ± 8.4 μg/kg/h) (P = 0.02). The proportion of patients with NRS scores of 0 to 3 at 24 h was significantly higher in group B (85.4%, 106/124) than in group A (73.5%, 86/117) (P = 0.02). The proportion of patients not requiring postoperative intravenous rescue drugs was significantly higher in group B (78.2%, 97/124) than in group A (61.5%, 72/117) (P < 0.01).
Conclusion: The divided method of ML-ICB could reduce the intraoperative remifentanil dose, decrease the postoperative pain score at 24 h, and curtail postoperative intravenous rescue drug use, despite using half the total ropivacaine dose intraoperatively.
Keywords: Early mobilization; Intercostal nerve block; Numerical rating scale; Ropivacaine; Thoracoscopic surgery.
© 2023. The Author(s).
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Comment in
-
The nitty-gritty of pain research in thoracoscopic surgery.J Anesth. 2023 Dec;37(6):976-977. doi: 10.1007/s00540-023-03249-6. Epub 2023 Aug 31. J Anesth. 2023. PMID: 37650982 No abstract available.
-
Correct interpretation of between-group statistical differences in analgesic efficacy of different intercostal nerve block modalities.J Anesth. 2024 Feb;38(1):141-142. doi: 10.1007/s00540-023-03258-5. Epub 2023 Sep 21. J Anesth. 2024. PMID: 37733074 No abstract available.
References
-
- Falcoz PE, Puyraveau M, Thomas PA, Decaluwe H, Hürtgen M, Petersen RH, Hansen H, Brunelli A, Brunelli A, Raemdonck DV, Dahan M, Rocco G, Decaluwe H, Varela G, Salaty M, Ruffini E, Filosso P, Scarci M, Bille A, D’journo XB, Szanto Z, Venuta F, Hansen H, Hürtgen M, Horsleben R, Schmidt T, Piwkowski C, Gossot D, Siebenga J, Brunelli A, Decaluwe H. Video-assisted thoracoscopic surgery versus open lobectomy for primary non-small-cell lung cancer: a propensity-matched analysis of outcome from the European Society of Thoracic Surgeon database. Eur J Cardiothorac Surg. 2016;49:602–9. doi: 10.1093/ejcts/ezv154. - DOI - PubMed
-
- Bendixen M, Jørgensen OD, Kronborg C, Andersen C, Licht PB. Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early-stage lung cancer: a randomized controlled trial. Lancet Oncol. 2016;17:836–844. doi: 10.1016/S1470-2045(16)00173-X. - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
